Enquiry Now
Loading...
| A03183 | Pages: NA | Aug 2021 | 4143 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Vasculitis Treatment Market
Request Now !Vasculitis is a medical condition where the inflammation of blood vessels takes place that affects the skin, eye, brain, or certain internal organs. The associated symptoms observed include fatigue, weakness, weight loss, muscle pain, congestive heart failure, malaise, and others. Treatment techniques include various medications such as corticosteroids and cytotoxic medicines.
The major factors that contribute to the growth of the vasculitis treatment market include increasing prevalence of chronic diseases due to sedentary lifestyles, rise in geriatric population who are more prone to cardiovascular diseases, high demand for minimally invasive procedures, better healthcare infrastructure, and technological advancements & innovations that lead to intense competition among key players. However, lack of trained professionals and stringent governmental regulations for these drugs restrict the market growth. Recent innovations, which embed the introduction of innovative ideas such as use of sequential magnetic resonance imagingmagnetic resonance angiography (MRIMRA) will provide better results to the physicians and allow them to work more efficiently, thus fostering the market growth.
The global vasculitis treatment market is segmented on the basis of drug class, disease type, end user, and region. Based on drug class, it is divided into corticosteroids, immunosuppressants, and biologics. Based on disease type, the market is categorized into small vessel and medium vessel vasculitis. According to end user, the market is divided into government, hospitals, medical clinics, and others. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players that operate in this market include GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Celgene Corporation, Ablynx, Gilead, Novartis AG, Bristol-Myers Squibb Company, Novo Nordisk A/S, Eli Lilly and Company, and Merck & Co., Inc.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 VASCULITIS TREATMENT MARKET, BY DRUG CLASS
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CORTICOSTEROIDS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. IMMUNOSUPPRESSANTS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. BIOLOGICS
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 VASCULITIS TREATMENT MARKET, BY DISEASE TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. SMALL VESSEL VASCULITIS
5.2.1. Market size and forecast
5.3. MEDIUM VESSEL VASCULITIS
5.3.1. Market size and forecast
CHAPTER 6 VASCULITIS TREATMENT MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. GOVENRMENT
6.2.1. Market size and forecast
6.3. HOSPITALS
6.3.1. Market size and forecast
6.4. MEDICAL CLINICS
6.4.1. Market size and forecast
6.5. OTHERS
6.5.1. Market size and forecast
CHAPTER 7 VASCULITIS TREATMENT MARKET, BY REGION
7.1. OVERVIEW
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast
7.2.4. North America vasculitis treatment market by drug class
7.2.5. North America vasculitis treatment market by disease type
7.2.6. North America vasculitis treatment market by end user
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast
7.3.4. Europe vasculitis treatment market by drug class
7.3.5. Europe vasculitis treatment market by disease type
7.3.6. Europe vasculitis treatment market by end user
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.6. Taiwan market size and forecast
7.4.3.7. Rest of Asia-Pacific market size and forecast
7.4.4. Asia-Pacific vasculitis treatment market by drug class
7.4.5. Asia-Pacific vasculitis treatment market by disease type
7.4.6. Asia-Pacific vasculitis treatment market by end user
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. Saudi Arabia market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast
7.5.4. LAMEA vasculitis treatment market by drug class
7.5.5. LAMEA vasculitis treatment market by disease type
7.5.6. LAMEA vasculitis treatment market by end user
CHAPTER 8 COMPANY PROFILES
8.1. GLAXOSMITHKLINE PLC
8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments
8.2. F. HOFFMANN-LA ROCHE AG
8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. CELGENE CORPORATION
8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. NOVARTIS AG
8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.5. GILEAD
8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. BRISTOL-MYERS SQUIBB COMPANY
8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments
8.7. NOVO NORDISK A/S
8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments
8.8. ELI LILLY AND COMPANY
8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments
8.9. MERCK & CO., INC.
8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments
8.10. ABLYNX
8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
